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This document is a comment on the X PRIZE validation protocol written by Kedes et al.  
(2011).  We propose several modifications which we think will improve the fairness and 
transparency  of  the  contest  while  keeping  the  cost  of  the  validation  process  under 
control. 
Comment 1.
A key goal is to ensure the judging process is as transparent and open as possible.  To 
this end, a sample public dataset (“Public Dataset”) as well as free and open-source 
software for scoring genome assemblies against this sample Public Dataset, should be 
provided by the X PRIZE Foundation.  This will  allow contestants to score their own 
assemblies  in  advance  of  the  actual  competition.  The  Public  Dataset  should  be 
generated from a set of 100 Public Genomes. The National Center for Supercomputing 
Applications (NCSA) should also provide access to the Public Dataset and open source 
software for scoring genome assemblies in advance of the actual contest.
Comment 2. 
Use random sequencing of long DNA fragments for haploid phasing, structural variants, 
and sequence fidelity. Fosmid libraries are an established technique for this but other 
techniques are possible;  see Fan et  al.,  (2011),  Kitzman et  al.  (2011),  Zhang et  al. 
(2006a,b).  Use of long DNA fragments would also:
• Eliminate the need for trios to assess haplotype accuracy. 
• Reduce or eliminate the need for targeted resequencing of highly polymorphic 
regions.
• Reduce or eliminate the need for deep distant pair-end/mate-pair resequencing 
for assessing structural variants.
Random fragments could be isolated from all of the 100 Public Datasets (see above) 
and Test DNA samples. Sequences from these fragments would be assembled de-novo 
to maximize the discovery of indels and structural variants. The exact configuration of 
reads would determine the ability to accurately de-novo assemble repetitive regions. If 
Fosmids are used, then assembled sequences would be anchored on both ends to a 



































microbial sequence.  These data would serve as a template to compare the accuracy, 
completeness, and diploid assembly (haploid phasing) of contestant genome assemblies 
for each cell line. 
Comment 3.
The  Archon  Genomics  X  PRIZE  Validation  Protocol  proposed  that  any  assembled 
fragment that cannot be reasonably aligned to the extant reference genomes (possibly 
including primates) would not be used for validation. Such assembled fragments could 
be included if their sequences can be verified present in other human genomes (e.g., by 
PCR analysis).  In  any case,  any  such tests  should  be included in  the  open source 
software provided to contestants as part of the validation protocol and made available in 
conjunction with the Public Dataset. 
In total, a minimum of 200 gigabases of alignable data would be generated for each of 
the Public and the Validation Test datasets (a minimum 30x coverage of 30 megabases 
from each sample and variable coverage of additional regions in each sample). In this 
way, one would expect that every position in the human genome would be interrogated 
by these data sets. 
In particular, one would expect that every genome will have some assembled fragments 
from the HLA complex (and other repetitive regions) and that the whole region will be 
reasonably represented in both the Public and Validation Datasets. As an optional step 
to improve de-novo assembly of highly repetitive regions (such as those derived from the 
HLA complex),  a few long DNA fragment libraries could be sequenced using a more 
expensive technology that delivered either longer reads and/or larger mate-pair gaps.   
Comment 4.
Sequencing  accuracy  can  be  inexpensively  assessed  at  defined  genomic  loci  via 
genotyping “in duplicate”.  Using the same platform and an additional  reference DNA 
sample, one should detect copy number variants (CNVs). The sequence accuracy of at 
least one million common SNPs and all detectable CNVs should be determined for each 
test  genome.  Each  sample  should  be  assessed  twice  to  minimize  call  errors  and 
discordant results between duplicate runs should be discarded.  
Comment 5.
Genotyping results can be combined with random sequencing of long DNA fragments to 
ensure internal validity.  This can help ensure that artifacts are minimized and can drive 
automated  identification  of  loci  that  require  further  PCR  analysis  and  sequencing. 
Demonstrating  this  process  on  the  Public  Data  set  will  help  ensure  that  the  final 
Validation Data set is of the highest quality.  
Comment 6. Suggestions for Needed Software Development
It should be noted that the primary data produced by likely sequencing and genotyping 
facilities will not be in a format that allows a straightforward comparison with the 
contestant data. Along with the Public Dataset, open source software will need to be 



































• Comparison and cross-validation of the genotyping data obtained from different 
technical platforms
• De-novo assembly of long DNA fragments from raw reads (finding substitutions, 
indels and structural variations across the fragment—all of which should be in 
phase),  cross-validation  with  genotyping  and  targeted  sequencing  (and  if 
Fosmids are used, anchoring of contigs on the reference assembly). 
• From all of the above, preparation of a sequence-based validation dataset that 
can be used for scoring the sequences submitted by contestants. 
Comment 7. Suggestions for the Data Deposition and Format 
The  data  submission  requirements  of  the  Validation  Protocol  should  be  modified. 
Contestants should submit data in a simple plain-text format that will be specified by 
Archon Genomics X PRIZE and specifically designed to facilitate scoring, subsequent 
publication,  and  clinical  utilization.  Software  should  be  provided  to  manipulate  this 
format.  Example  genomes  in  this  format  generated  on  the  Illumina,  SOLiD,  and 
Complete Genomics and possibly other platforms should be provided to accompany the 
Public Dataset. 
We agree that the data should be submitted to the Archon Genomics X PRIZE Judging 
Panel on two identical  hard disks, each containing a full  set  of  files but  they should 
include a manifest of corresponding cryptographic hashes, to avoid potential data loss 
due to file corruption. 
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